SCHEMBL5086984

SCHEMBL5086984

Cc1cc(Br)c(O)c(-c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
MAOB P27338 1/20 0.46
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
AKR1C1 Q04828 2/20 0.46
BACE1 P56817 2/20 0.45
ESR2 Q92731 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 2/20 0.43
AKR1C4 P17516 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PDE4B Q07343 1/20 0.41
F2 P00734 4/20 0.41
F10 P00742 4/20 0.41
PLG P00747 4/20 0.41
PLAU P00749 4/20 0.41
PRSS1 P07477 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13045187 0.91 CRHBP (0.48) CRHBPCRHR2MAOBAKR1C3AKR1C2
SCHEMBL2528210 0.86 BACE1 (0.54) CRHBPCRHR2AKR1C3AKR1C2AKR1C1
SCHEMBL11134273 0.84 BACE1 (0.52) CRHBPCRHR2MAOBAKR1C3AKR1C2
SCHEMBL18171930 0.82 MEN1 (0.43) CRHBPCRHR2ALDH1A1MEN1KMT2A
SCHEMBL880200 0.81 GABRA1 (0.56) ALDH1A1MEN1KMT2AF2F10
SCHEMBL8986922 0.80 ESR2 (0.52) MAOBBACE1ESR2HDAC7ALDH1A1
SCHEMBL28220857 0.80 MAOB (0.49) CRHBPCRHR2MAOBBACE1ESR2
SCHEMBL8898818 0.80 GABRA1 (0.64) CRHBPCRHR2MAOBAKR1C3AKR1C2
SCHEMBL21345872 0.80 CRHBP (0.76) CRHBPCRHR2AKR1C3AKR1C2AKR1C1
SCHEMBL10014387 0.79 PDCD1 (0.50) BACE1ESR2HDAC7ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3105236-A1 BENZOTHIAZOLE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE (NO.5) LIMITED (GB) 2016-12-21 EP disclosed
WO-2015123230-A1 BENZOTHIAZOLE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-08-20 WO disclosed
EP-1501840-B1 BRIDGED BI-AROMATIC LIGANDS, COMPLEXES, CATALYSTS, PROCESSES FOR POLYMERIZING AND POLYMERS THEREFROM SYMYX SOLUTIONS INC (US) 2010-12-22 EP disclosed
US-7705157-B2 Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts SYMYX SOLUTIONS, INC. (US) 2010-04-27 US disclosed
US-7705157-B2 Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts SYMYX SOLUTIONS, INC. (US) 2010-04-27 US disclosed
US-20100048841-A1 PHENOL-HETEROCYCLIC LIGANDS, METAL COMPLEXES, AND THEIR USES AS CATALYSTS SYMYX SOLUTIONS, INC. (US) 2010-02-25 US disclosed
US-20100048841-A1 PHENOL-HETEROCYCLIC LIGANDS, METAL COMPLEXES, AND THEIR USES AS CATALYSTS SYMYX SOLUTIONS, INC. (US) 2010-02-25 US disclosed
US-7659415-B2 Bridged bi-aromatic ligands, catalysts, processes for polymerizing and polymers therefrom SYMYX SOLUTIONS, INC. (US) 2010-02-09 US disclosed
US-7659415-B2 Bridged bi-aromatic ligands, catalysts, processes for polymerizing and polymers therefrom SYMYX SOLUTIONS, INC. (US) 2010-02-09 US disclosed
US-20080269470-A1 Bridged Bi-Aromatic Ligands, Catalysts, Processes For Polymerizing And Polymers Therefrom SYMYX TECHNOLOGIES, INC. (US) 2008-10-30 US disclosed
US-7241715-B2 Bridged bi-aromatic ligands, catalysts, processes for polymerizing and polymers therefrom SYMYX TECHNOLOGIES, INC. (US) 2007-07-10 US disclosed
US-7241715-B2 Bridged bi-aromatic ligands, catalysts, processes for polymerizing and polymers therefrom SYMYX TECHNOLOGIES, INC. (US) 2007-07-10 US disclosed
EP-1498178-A2 Transition metal complex, process for producing the same, olefin polymerization catalyst containing the transition metal complex and process for producing olefin polymers Sumitomo Chemical Company, Limited (JP) 2005-01-19 EP disclosed
CN-1185236-C Transition metal compound, its producing process olefine polymerization catalyst containing the same transition metal compound and process for producing olefine polymer SUMITOMO CHEMICAL CO (JP) 2005-01-19 CN disclosed
EP-0842939-B1 OLEFIN POLYMERIZATION CATALYST CONTAINING A TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING OLEFIN POLYMERS SUMITOMO CHEMICAL CO (JP) 2004-10-06 EP disclosed
US-6329478-B1 SOLUBILITY IN SATURATED HYDROCARBON SOLVENTS SUMITMO CHEMICAL COMPANY, LIMITED 2001-12-11 US disclosed
CN-1310183-A Transition metal compound, its producing process olefine polymerization catalyst containing the same transition metal compound and process for producing olefine polymer SUMITOMO CHEMICAL CO (JP) 2001-08-29 CN disclosed
CN-1068884-C Transition metal complex, process for producing the same, olefin polymerization catalyst containing the transition metal complex, and process for producing olefin polymer SUMITOMO CHEM IND (JP) 2001-07-25 CN disclosed
CN-1193323-A Transition metal complex, process for producing the same, olefin polymerization catalyst containing the transition metal complex, and process for producing olefin polymer SUMITOMO CHEM IND (JP) 1998-09-16 CN disclosed
EP-0842939-A1 TRANSITION METAL COMPLEX, PROCESS FOR THE PREPARATION THEREOF, POLYMERIZATION CATALYST FOR OLEFINS CONTAINING THE COMPLEX, AND PROCESS FOR PRODUCING OLEFIN POLYMERS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269470-A1 Bridged Bi-Aromatic Ligands, Catalysts, Processes For Polymerizing And Polymers Therefrom WEE1, WASF2, WEE2 CRHBP 981/4885CRHR2 1337/4885MAOB 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.